Voors AA - Search Results

1

A novel approach to drug development in heart failure: towards personalized medicine.

Liu LC, Voors AA, Valente MA, van der Meer P. Liu LC, et al. Among authors: voors aa. Can J Cardiol. 2014 Mar;30(3):288-95. doi: 10.1016/j.cjca.2013.12.005. Epub 2013 Dec 17. Can J Cardiol. 2014. PMID: 24565253 Review.

2

Angiotensin receptors in the cardiovascular system.

Wagenaar LJ, Voors AA, Buikema H, van Gilst WH. Wagenaar LJ, et al. Among authors: voors aa. Can J Cardiol. 2002 Dec;18(12):1331-9. Can J Cardiol. 2002. PMID: 12518185 Review.

3

Erythropoietin in cardiovascular diseases.

van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. van der Meer P, et al. Among authors: voors aa. Eur Heart J. 2004 Feb;25(4):285-91. doi: 10.1016/j.ehj.2003.11.017. Eur Heart J. 2004. PMID: 14984916 Review.

4

Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure.

van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ. van der Meer P, et al. Among authors: voors aa. J Am Coll Cardiol. 2004 Jul 7;44(1):63-7. doi: 10.1016/j.jacc.2004.03.052. J Am Coll Cardiol. 2004. PMID: 15234408 Free article.

5

Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction.

Smilde TD, Hillege HL, Voors AA, Dunselman PH, Van Veldhuisen DJ. Smilde TD, et al. Among authors: voors aa. Am J Cardiol. 2004 Jul 15;94(2):240-3. doi: 10.1016/j.amjcard.2004.03.075. Am J Cardiol. 2004. PMID: 15246913

6

Hemoglobin levels and 30-day mortality in patients after myocardial infarction.

Lipsic E, van der Horst IC, Voors AA, van der Meer P, Nijsten MW, van Gilst WH, van Veldhuisen DJ, Zijlstra F. Lipsic E, et al. Among authors: voors aa. Int J Cardiol. 2005 Apr 20;100(2):289-92. doi: 10.1016/j.ijcard.2004.10.043. Int J Cardiol. 2005. PMID: 15823637

7

The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy.

van der Meer P, De Boer RA, White HL, van der Steege G, Hall AS, Voors AA, van Veldhuisen DJ. van der Meer P, et al. Among authors: voors aa. J Card Fail. 2005 May;11(4):279-84. doi: 10.1016/j.cardfail.2004.11.006. J Card Fail. 2005. PMID: 15880336 Clinical Trial.

8

Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.

van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. van der Meer P, et al. Among authors: voors aa. J Am Coll Cardiol. 2005 Jul 5;46(1):125-33. doi: 10.1016/j.jacc.2005.03.044. J Am Coll Cardiol. 2005. PMID: 15992646 Free article.

9

Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk.

Voors AA, de Kam PJ, van den Berg MP, Borghi C, Hochman JS, van Veldhuisen DJ, van Gilst WH. Voors AA, et al. Cardiovasc Drugs Ther. 2005 Mar;19(2):119-24. doi: 10.1007/s10557-005-0444-9. Cardiovasc Drugs Ther. 2005. PMID: 16025230 Clinical Trial.

10

Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure.

van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH. van der Meer P, et al. Among authors: voors aa. Circulation. 2005 Sep 20;112(12):1743-7. doi: 10.1161/CIRCULATIONAHA.105.549121. Circulation. 2005. PMID: 16172283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

805 results

Search Page

Filters